EFFICACY OF VENETOCLAX plus OBINUTUZUMAB plus IBRUTINIB COMPARED TO ALTERNATIVE THERAPEUTIC OPTIONS IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (FIT POPULATION): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

被引：0
|
作者：
Stozek-Tutro, A. [1 ]
Reczek, M. [2 ]
Kawalec, P. [3 ]
机构：
[1] Jagiellonian Univ, Doctoral Sch Med & Hlth Sci, Med Coll, Crocow, MA, Poland
[2] HTA Consulting, Krakow, Poland
[3] Jagiellonian Univ, Inst Publ Hlth, Med Coll, Krakow, Poland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO182
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials
    Tanriverdi, Lokman Hekim
    Sarici, Ahmet
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S349 - S349
  • [2] Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia A Nonrandomized Phase 2 Trial
    Jain, Nitin
    Keating, Michael
    Thompson, Philip
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev
    Sasaki, Koji
    Fowler, Nathan
    Kadia, Tapan
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Wei, Chongjuan
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William G.
    JAMA ONCOLOGY, 2021, 7 (08) : 1213 - 1219
  • [3] THE BUDGET IMPACT OF VENETOCLAX PLUS OBINUTUZUMAB FOR FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN SAUDI ARABIA
    Alrajhi, A. M.
    Al-Abdulkarim, H.
    Khan, M.
    Alkhudair, N.
    Alshehri, H.
    Fasseeh, A.
    Aziz, A. Abd-El
    Elezbawy, B.
    Abaza, S.
    Ahmed, Y.
    Sheriba, A. N.
    Semida, A.
    Alnajjar, F.
    VALUE IN HEALTH, 2024, 27 (12)
  • [4] First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Novak, Jan
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Kwei, Kevin
    Dai, Sandra
    Hsu, Emily
    Dean, James P.
    Flinn, Ian W.
    HAEMATOLOGICA, 2022, 107 (09) : 2108 - 2120
  • [5] Phase 2 CAPTIVATE Results of Ibrutinib Plus Venetoclax in First-Line Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 2 - 4
  • [6] Comparative Efficacy of Ibrutinib Versus Obinutuzumab plus Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Van Sanden, Suzy
    Baculea, Simona
    Diels, Joris
    Cote, Sarah
    ADVANCES IN THERAPY, 2017, 34 (07) : 1650 - 1661
  • [7] Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View
    Do, Ngoc
    Thielen, Frederick W.
    VALUE IN HEALTH, 2023, 26 (04) : 477 - 486
  • [8] Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
    Moreno, Carol
    Solman, Isabelle G.
    Tam, Constantine S.
    Grigg, Andrew
    Scarfo, Lydia
    Kipps, Thomas J.
    Srinivasan, Srimathi
    Mali, Raghuveer Singh
    Zhou, Cathy
    Dean, James P.
    Szafer-Glusman, Edith
    Choi, Michael
    BLOOD ADVANCES, 2023, 7 (18) : 5294 - 5303
  • [9] Real-world time to discontinuation of first-line venetoclax plus obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, : 1227 - 1235
  • [10] Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Samoilova, Olga
    Novak, Jan
    Ben-Yehuda, Dina
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Hsu, Emily
    Zhou, Cathy
    Clow, Fong
    James, Danelle F.
    Styles, Lori
    Flinn, Ian W.
    BLOOD, 2018, 132
12345